EP 0991411 A4 20000531 - TREATMENT FOR PULMONARY FIBROSIS
Title (en)
TREATMENT FOR PULMONARY FIBROSIS
Title (de)
BEHANDLUNG VON LUNGENFIBROSE
Title (fr)
TRAITEMENT DE LA FIBROSE PULMONAIRE
Publication
Application
Priority
IL 9700115 W 19970331
Abstract (en)
[origin: WO9843642A1] A composition for treating pulmonary fibrosis and a method of using and manufacturing the composition are provided. The composition includes a quinazolinone derivative, preferably Halofuginone. The preferred method of administration is by inhalation, preferably with a pharmaceutically acceptable carrier in the form of an aerosol.
IPC 1-7
IPC 8 full level
A61K 9/12 (2006.01); A61K 31/517 (2006.01); A61P 11/00 (2006.01); C07D 401/06 (2006.01)
CPC (source: EP)
A61K 31/517 (2013.01); A61P 11/00 (2017.12)
Citation (search report)
- [E] WO 9834613 A1 19980813 - AGRICULTURAL RES ORG [IL], et al
- [X] NAGLER A ET AL: "Reduction in pulmonary fibrosis in vivo by halofuginone.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, (1996 OCT) 154 (4 PT 1) 1082-6., XP000901078
- [X] NAGLER, A. (1) ET AL: "Reduction of pulmonary fibrosis by halofuginone, a specific inhibitor of collagen type I.", BLOOD, (1996) VOL. 88, NO. 10 SUPPL. 1 PART 1-2, PP. 416A. MEETING INFO.: THIRTY-EIGHTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY ORLANDO, FLORIDA, USA DECEMBER 6-10, 1996, XP000901181
- See references of WO 9843642A1
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9843642 A1 19981008; AU 2042097 A 19981022; AU 737094 B2 20010809; CA 2285350 A1 19981008; EP 0991411 A1 20000412; EP 0991411 A4 20000531; JP 2001518062 A 20011009
DOCDB simple family (application)
IL 9700115 W 19970331; AU 2042097 A 19970331; CA 2285350 A 19970331; EP 97908480 A 19970331; JP 52550097 A 19970331